Home › Cancer (all types) › NCT07382752

Decoupling Immunotherapy Toxicity and Cancer Response

Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age ≥ 18 years
2. Plan to start immune checkpoint inhibitor for cancer therapy

Exclusion Criteria:

1. No baseline blood collection prior to initiation
2. At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator

About the study

This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.

Sponsor: M.D. Anderson Cancer Center · Participants: 1,200 · Started: Jan 9, 2026

Contact the study team

• Nicolas Palaskas, MD · Phone: 832-750-1109

Official record on ClinicalTrials.gov — NCT07382752

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.